Measuring Attractiveness for Abuse of Prescription Opioids

被引:42
|
作者
Butler, Stephen F. [1 ]
Fernandez, Kathrine C. [1 ]
Chang, Alan [1 ]
Benoit, Christine [1 ]
Morey, Leslie C. [2 ]
Black, Ryan [1 ]
Katz, Nathaniel [3 ]
机构
[1] Inflexxion Inc, Newton, MA 02464 USA
[2] Texas A&M Univ, College Stn, TX USA
[3] Analges Res, Needham, MA USA
关键词
Prescription Opioids; Attractiveness; Abuse; ORAL OXYCODONE; PSYCHOMOTOR; MORPHINE;
D O I
10.1111/j.1526-4637.2009.00736.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Objective. Prescription opioids are the second most misused/abused drug in the United States behind only marijuana. Recreational prescription opioid users appear to prefer some products over others; however, the extent to which attributes of any particular formulation account for such preferences has yet to be determined. The Opioid Attractiveness Technology Scaling was developed to identify the particular features of a prescription opioid that are relevant to its attractiveness for recreational use, and to use these features to model attractiveness for recreational use of particular prescription opioid formulations. Design. Four hundred and ninety-one self-reported recreational prescription opioid users identified 43 product features as being relevant to determining whether a product is "attractive" or "unattractive" for recreational use. Average ratings were used to determine appropriate weights to be applied to the features. A factor analysis yielded 10, highly differentiated factors. Five hundred and sixty-four prescription opioid abusers were then asked to rate the extent to which the 43 features identified in Study 1 were relevant to specific prescription opioid products they had used. Results. Respondents provided an overall preference rating of these products and a model was created. A random intercept model yielded a significant pseudo R-2 of 0.14 (chi-square = 310.02, degrees of freedom [df] = 10, P < 0.001). The model fit least well, albeit significantly, for abusers who preferred to swallow the drug (pseudo R-2 = 0.06; chi-square = 55.52, df = 10, P < 0.001) and best for those who preferred to inject (pseudo R-2 = 0.37; chi-square = 199.34, df = 10, P < 0.001). Conclusions. The relevance of the model is discussed along with possible modifications that might allow prediction of "attractiveness" of "abuse deterrent" formulations that have not yet been marketed.
引用
收藏
页码:67 / 80
页数:14
相关论文
共 50 条
  • [21] The Economic Burden of Abuse of Prescription Opioids: A Systematic Literature Review from 2012 to 2017
    Marcia Reinhart
    Lauren M. Scarpati
    Noam Y. Kirson
    Cody Patton
    Nina Shak
    Jennifer G. Erensen
    [J]. Applied Health Economics and Health Policy, 2018, 16 : 609 - 632
  • [22] Ototoxicity of Prescription Opioids
    Hedge, M. W.
    Smolinske, S. C.
    Bailey, J. E.
    Dart, R. C.
    [J]. CLINICAL TOXICOLOGY, 2009, 47 (07) : 745 - 745
  • [23] Abuse and dependence on prescription opioids in adults: a mixture categorical and dimensional approach to diagnostic classification
    Wu, L-T
    Woody, G. E.
    Yang, C.
    Pan, J-J
    Blazer, D. G.
    [J]. PSYCHOLOGICAL MEDICINE, 2011, 41 (03) : 653 - 664
  • [24] The Economic Burden of Abuse of Prescription Opioids: A Systematic Literature Review from 2012 to 2017
    Reinhart, Marcia
    Scarpati, Lauren M.
    Kirson, Noam Y.
    Patton, Cody
    Shak, Nina
    Erensen, Jennifer G.
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2018, 16 (05) : 609 - 632
  • [25] MISUSE AND ABUSE OF PRESCRIPTION OPIOIDS: AN EDUCATIONAL INTERVENTION FOR AT-RISK ADULTS IN DILLON, MT
    McCormick, R.
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2014, 62 (01) : 164 - 164
  • [26] Abuse Liability of Prescription Opioids Compared to Heroin in Morphine-Maintained Heroin Abusers
    Sandra D Comer
    Maria A Sullivan
    Robert A Whittington
    Suzanne K Vosburg
    William J Kowalczyk
    [J]. Neuropsychopharmacology, 2008, 33 : 1179 - 1191
  • [27] Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers
    Comer, Sandra D.
    Sullivan, Maria A.
    Whittington, Robert A.
    Vosburg, Suzanne K.
    Kowalczyk, William J.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2008, 33 (05) : 1179 - 1191
  • [28] Prescription opioids, abuse and public health in Canada: is fentanyl the new centre of the opioid crisis?
    Fischer, Benedikt
    Russell, Cayley
    Murphy, Yoko
    Kurdyak, Paul
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 (12) : 1334 - 1336
  • [29] Prescription Opioids and Addiction
    Miller, Norman S.
    Gold, Mark S.
    [J]. PSYCHIATRIC ANNALS, 2015, 45 (10) : 516 - 521
  • [30] Prescription Drug Monitoring and Dispensing of Prescription Opioids
    Brady, Joanne E.
    Wunsch, Hannah
    DiMaggio, Charles
    Lang, Barbara H.
    Giglio, James
    Li, Guohua
    [J]. PUBLIC HEALTH REPORTS, 2014, 129 (02) : 139 - 147